6 October 2021
CuraVac was honored to participate in the International Symposium on the Treatment of Brain and Neurology Disorders held in Taipei, Taiwan. Among other expert speakers from Asia, Taiwan and Europe, Dr. Stéphane Huberty M.D., gave a keynote presentation on the new research and current development of CuraVac’s Therapeutic Vaccines.
19 – 22 June 2017
Thank you for visiting us at Bio 2017 in San Diego on the Belgian Booth and/or meeting us thru One-on-One Partnering.
15 – 17 MAY 2017
7 – 9 November 2016
Thank you vor visiting us at Bio Europe 2016 in Köln.
5 – 9 June 2016
Thank you for visiting us at Bio 2016 in San Francisco.
2 – 4 November 2015
Thank you for meeting us at Bio Europe 2015 in Munich.
CuraVac’s MG Therapeutic Vaccine receives Clinical Trial Authorization (CTA) in Belgium and the Ethical Committee of the University Hospital of Antwerp (UZA) gives its authorization for a Phase 1b trial on 24 to 32 patients.
15 – 19 June 2015
Thank you for meeting us at Bio 2015 in Philadelphia.
10 December 2014
CURAVAC WON THE BEST PRESENTATION AWARD AT THE EUROPEAN VENTURE CONTEST 2014 (December 2014)
3 – 5 November 2014
Thank you for meeting us at Bio Europe 2014 in Frankfurt.
9 October 2014
CURAVAC WON THE BEST PRESENTATION AWARD AT THE LIFE SCIENCES INVESTMENT FORUM (October 2014).
23 – 26 June 2014
Thank you for visiting us at Bio 2014 in San Diego on the Belgian Pavilion.
CuraVac will present the company and the myasterix project at BioVision on June 6th in Lyon, France.
CuraVac was present at Buzz4Bio.
CuraVac is proud to announce the start of the Myasterix project.
An independent Jury deems the Myasterix project one of the seven best therapeutic vaccine projects and recommends that the European Commission subsidizes the project.
CuraVac attends the Bio 2013 convention in Chicago.
CuraVac creates the Myasterix consortium.
CuraVac attends the Bio 2012 convention in Boston.